Anthony Maida

Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA.

PharmaNet, Inc. researches and develops new drugs and provides clinical development & consulting services. Its services include strategic planning, data management, bio-statistics, site management, study monitoring, protocol/CRF design, project management, information technology, quality control and assurance and regulatory affairs. The company was founded in 1996 by Jeffrey P. McMullen and is headquartered in Princeton, NJ.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

The Society of Neuro-Oncology is a non-profit organization, which engages in the research, education, and collaboration for central nervous system tumors in children and adults. The company was founded on January 31, 1996 and is headquartered in Bellaire, TX.

The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI.

The Society of Toxicology is an organization that unites 8,000 professionals in the field of toxicology from all over the world. The non-profit company is based in Reston, VA. The company's goal is to promote scientific advancements and provide support to toxicologists.

Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA.

The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations.